Quilter Plc Has $3.33 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Quilter Plc reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,023 shares of the biopharmaceutical company’s stock after selling 5,005 shares during the quarter. Quilter Plc’s holdings in Gilead Sciences were worth $3,327,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in GILD. AMF Tjanstepension AB lifted its stake in Gilead Sciences by 14.7% in the third quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock valued at $33,645,000 after acquiring an additional 51,390 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its position in shares of Gilead Sciences by 398.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 10,717 shares of the biopharmaceutical company’s stock valued at $898,000 after purchasing an additional 8,565 shares during the period. Valeo Financial Advisors LLC raised its position in shares of Gilead Sciences by 12.6% in the third quarter. Valeo Financial Advisors LLC now owns 9,539 shares of the biopharmaceutical company’s stock valued at $800,000 after purchasing an additional 1,070 shares during the period. Silverlake Wealth Management LLC bought a new position in shares of Gilead Sciences in the third quarter valued at approximately $210,000. Finally, Westend Capital Management LLC bought a new position in shares of Gilead Sciences in the third quarter valued at approximately $6,792,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

NASDAQ GILD opened at $96.04 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $100.51. The company has a market capitalization of $119.69 billion, a PE ratio of 1,067.11, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The firm’s 50 day moving average is $93.04 and its 200-day moving average is $86.76.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the business earned $2.29 earnings per share. The firm’s revenue was up 7.0% on a year-over-year basis. Equities research analysts anticipate that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 572,824 shares of company stock valued at $53,611,715. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent analyst reports. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $74.00 to $96.00 in a research report on Monday, October 21st. Mizuho boosted their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Finally, Piper Sandler boosted their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.